Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Pediatr Res ; 63(4): 394-7, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18356745

ABSTRACT

Erythropoietin (Epo) is an erythropoietic, neurotropic, and angiogenic factor, and may be involved in retinal development. Studies in adult diabetic retinopathy patients reveal significantly elevated vitreal Epo concentrations. It is unknown whether Epo plays a similar role in retinopathy of prematurity. We sought to determine whether Epo is present in the normally developing human eye. Fetal serum and vitreous samples were obtained from 12 to 24 wk gestation. RNA was extracted from isolated retina for Epo mRNA and hypoxia inducible factor-1alpha (HIF) mRNA determination by real-time polymerase chain reaction. Fetal serum was isolated from the umbilical cord. Serum and vitreous samples were analyzed for Epo protein by enzyme-linked immunosorbent serologic assay. In fetal retina, Epo mRNA increased with increasing gestational age, while HIF mRNA remained constant. Epo protein increased with increasing gestation in both vitreous and serum. At each gestational group measured (12-14, 15-17, 18-20, and 21-24 wk), Epo concentrations were significantly greater in vitreous than in serum (p < 0.05). Epo mRNA and protein concentrations increase with increasing gestational age and are greater in the vitreous than serum. We speculate that changes in Epo production following preterm delivery might affect retinal vascular development.


Subject(s)
Erythropoietin/metabolism , Eye/embryology , Eye/metabolism , RNA, Messenger/metabolism , Aging/metabolism , Erythropoietin/blood , Erythropoietin/genetics , Gestational Age , Humans , Hypoxia-Inducible Factor 1, alpha Subunit/genetics , Hypoxia-Inducible Factor 1, alpha Subunit/metabolism , Infant, Newborn , Retina/embryology , Retina/metabolism , Retinopathy of Prematurity/etiology , Retinopathy of Prematurity/metabolism , Vitreous Body/embryology , Vitreous Body/metabolism
2.
Cancer Res ; 63(15): 4620-5, 2003 Aug 01.
Article in English | MEDLINE | ID: mdl-12907641

ABSTRACT

Aberrant methylation of 5'CpG islands is a key epigenetic event in many human cancers. A PCR-based technique of methylated CpG island amplification followed by representational difference analysis was used to identify genes methylated in cancer. Two of the CpG islands identified mapped to the 5' untranslated region of the PAX5 alpha and beta genes. These genes, located on chromosome 9p13, are transcribed from two distinct promoters and form two alternative first exons that are subsequently spliced to the common exons 2-10. The resulting splice variants encode two distinct transcription factors important in cell differentiation and embryonic development. Examination of the methylation status of each gene using methylation-specific PCR revealed that both genes are methylated in approximately 65% of breast and lung tumors. Bisulfite sequencing revealed dense methylation patterns within each 5'CpG island, strongly correlating with transcriptional silencing. Expression in cell lines with dense methylation of either the PAX5 alpha or beta promoter region was restored after treatment with the demethylating agent 5-Aza-2'-deoxycytidine. The PAX5 beta gene encodes for the transcription factor B cell-specific activating protein that, in turn, directly regulates CD19, a gene shown to negatively control cell growth. A strong association was observed between PAX5 beta methylation and loss of expression of the CD19 gene demonstrating that inactivation of the PAX5 beta gene likely contributes to neoplastic development by inhibiting growth regulation through effects on CD19 gene expression. Recent studies have demonstrated the importance of PAX5 gene alterations in human cancer. Our results are the first to identify aberrant promoter methylation as a common mechanism for dysregulation of these genes in solid tumors.


Subject(s)
Azacitidine/analogs & derivatives , Breast Neoplasms/genetics , Carcinoma, Squamous Cell/genetics , DNA-Binding Proteins/genetics , Lung Neoplasms/genetics , Transcription Factors/genetics , Azacitidine/pharmacology , Breast Neoplasms/metabolism , Carcinoma, Squamous Cell/metabolism , CpG Islands , DNA Methylation , Decitabine , Gene Expression/drug effects , Humans , Lung Neoplasms/metabolism , Microsatellite Repeats/genetics , PAX5 Transcription Factor , Promoter Regions, Genetic , Tumor Cells, Cultured
3.
Cancer Res ; 62(8): 2370-7, 2002 Apr 15.
Article in English | MEDLINE | ID: mdl-11956099

ABSTRACT

Recent studies from our laboratory suggest that gene-specific methylation changes in sputum could be good intermediate markers for the early detection of lung cancer and defining the efficacy of chemopreventive interventions. The purpose of our study was to determine the prevalence for aberrant promoter methylation of the p16, O(6)-methylguanine-DNA methyltransferase (MGMT), death-associated protein (DAP) kinase, and Ras effector homologue (RASSFIA) genes in nonmalignant bronchial epithelial cells from current and former smokers in a hospital-based, case control study of lung cancer. The relationship between loss of heterozygosity, at 9p and p16 methylation in bronchial epithelium and the prevalence for methylation of these four genes in sputum from cancer-free, current and former smokers were also determined. Aberrant promoter methylation of p16 was seen in at least one bronchial epithelial site from 44% of cases and controls. Methylation of the DAP kinase gene was seen in only 1 site from 5 cases and 4 controls, whereas methylation of the RASSFIA was not detected in the bronchial epithelium. Promoter methylation for p16 and DAP kinase was seen as frequently in bronchial epithelium from current smokers as from former smokers. No promoter methylation of these genes was detected in bronchial epithelium from never-smokers. Methylation of the p16 gene was detected in sputum from 23 of 66 controls. DAP kinase gene promoter methylation was also seen in sputum from 16 controls, and 8 of these subjects were positive for p16 methylation. Methylation of the MGMT gene was seen in sputum from 9 controls, whereas RASSFIA promoter methylation was only seen in 2 controls. The correlation between p16 status in the bronchial epithelium obtained from lung lobes that did not contain the primary tumor and the tumor itself was examined. Seventeen of 18 tumors (94%) showed an absolute concordance, being either methylated in the tumor and at least 1 bronchial epithelial site, or unmethylated in both tumor and bronchial epithelium. These results indicate that aberrant promoter hypermethylation of the p16 gene, and to a lesser extent, DAP kinase, occurs frequently in the bronchial epithelium of lung cancer cases and cancer-free controls and persists after smoking cessation. The strong association seen between p16 methylation in the bronchial epithelium and corresponding primary tumor substantiates that inactivation of this gene, although not transforming by itself, is likely permissive for the acquisition of additional genetic and epigenetic changes leading to lung cancer.


Subject(s)
Bronchi/physiology , DNA Methylation , Genes, Tumor Suppressor , Lung Neoplasms/genetics , Promoter Regions, Genetic , Smoking/genetics , Sputum/metabolism , Tumor Suppressor Proteins , Adult , Aged , Aged, 80 and over , Apoptosis Regulatory Proteins , Bronchi/metabolism , Bronchi/ultrastructure , Calcium-Calmodulin-Dependent Protein Kinases/genetics , Case-Control Studies , Cells, Cultured , Chromosomes, Human, Pair 9 , Death-Associated Protein Kinases , Epithelial Cells/metabolism , Epithelial Cells/physiology , Epithelial Cells/ultrastructure , Female , Genes, p16/physiology , Humans , Loss of Heterozygosity , Lung Neoplasms/etiology , Lung Neoplasms/metabolism , Male , Middle Aged , Neoplasm Proteins/genetics , O(6)-Methylguanine-DNA Methyltransferase/genetics , Smoking/adverse effects , Smoking/metabolism , Sputum/cytology
SELECTION OF CITATIONS
SEARCH DETAIL
...